Results 191 to 200 of about 121,509 (248)

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, EarlyView.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Chimeric antigen receptor-based cell therapy for treating urological tumors. [PDF]

Curr Urol
Tang H, Guo L, Zhang W, Tang D.
europepmc   +1 more source

Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost‐effectiveness analysis

British Journal of Haematology, EarlyView.
Summary To assess the cost‐effectiveness of blinatumomab plus chemotherapy for paediatric patients from Hong Kong public healthcare provider's perspective, a 10‐year Markov model was designed to simulate outcomes in paediatric patients with newly diagnosed standard‐risk B‐cell ALL at: (1) average risk and (2) high risk of relapse.
Mingjun Rui, Yin Ting Cheung, Hui Zhang, Qiran Wei, Yingcheng Wang, Jiaqi Shi, Chi Kong Li, Joyce H. S. You   +7 more
wiley   +1 more source

Emerging Chimeric Antigen Receptor-Immune Cell Therapy for Pancreatic Cancer: Mechanisms, Clinical Advances, and Future Perspectives. [PDF]

Oncol Res
Wang S, Wang M, Yao W.
europepmc   +1 more source

Transplantation outcomes in patients with Down syndrome‐associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies

British Journal of Haematology, EarlyView.
This nationwide study of 56 patients with Down syndrome‐associated acute lymphoblastic leukaemia (ALL) demonstrated that haematopoietic stem cell transplantation (HSCT) in complete remission (CR)1/2 yields comparable event‐free survival to non‐Down syndrome ALL.
Hisashi Ishida, Yasuhiro Okamoto, Hirotoshi Sakaguchi, Yasuyuki Arai, Tomoaki Ueda, Shunsuke Yamamoto, Mio Yano, Tomoko Yokosuka, Keiko Okada, Maho Sato, Shuhei Karakawa, Ryoji Kobayashi, Keisuke Kato, Katsuyoshi Koh, Toshihiro Fujiki, Kumiko Goi, Shoji Saito, Junko Takita, Takako Miyamura, Yuhki Koga, Nao Yoshida, Atsushi Sato, Moeko Hino, Ken Tabuchi, Yuki Arakawa   +24 more
wiley   +1 more source

Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment. [PDF]

World J Clin Oncol
Arjumand S, Raj A, Prattay KMR, Omer HBM, Azam F.   +4 more
europepmc   +1 more source

Chimeric antigen receptor (CAR) therapies for precise eradication of pathogenic cells in autoimmunity. [PDF]

Arthritis Res Ther
Kalliolias GD, Basdra EK, Papavassiliou AG.   +2 more
europepmc   +1 more source

Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy. [PDF]

Int J Mol Sci
Cohen I, Lebel E, Grisariu S, Avni B, Kfir-Erenfeld S, Asherie N, Zimran E, Vainstein V, Assayag M, Sharon TD, Alexander-Shani R, Bessig N, Shehadeh A, Ishtay A, Schlossberg M, Pick M, Gatt ME, Bdolah-Abram T, Stepensky P, Elias S.   +19 more
europepmc   +1 more source

A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends. [PDF]

Biomark Res
Lai C, Hu J, Wu Z, He K, Li J, Zhu W, Liu C, He W, Xu K.   +8 more
europepmc   +1 more source

Chimeric antigen receptor dendritic cells suppress melanoma growth in preclinical cancer models. [PDF]

J Immunother Cancer
Minnee J, Wong WZ, Russell BS, Semana JL, Li R, Landau NR, Tada T.   +6 more
europepmc   +1 more source